Aligos Therapeutics (NASDAQ:ALGS) vs. X4 Pharmaceuticals (NASDAQ:XFOR) Critical Analysis

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Aligos Therapeutics and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aligos Therapeutics -197.01% -206.30% -99.45%
X4 Pharmaceuticals -474.74% -49.62% -30.80%

Risk and Volatility

Aligos Therapeutics has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aligos Therapeutics and X4 Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aligos Therapeutics $2.19 million 4.07 -$24.19 million ($6.35) -0.22
X4 Pharmaceuticals $35.11 million 8.61 -$79.20 million ($0.67) -4.55

Aligos Therapeutics has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aligos Therapeutics and X4 Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics 1 0 5 1 2.86
X4 Pharmaceuticals 1 1 4 0 2.50

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 2,601.75%. X4 Pharmaceuticals has a consensus target price of $11.25, suggesting a potential upside of 268.85%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than X4 Pharmaceuticals.

Summary

Aligos Therapeutics beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Aligos Therapeutics

(Get Free Report)

Aligos Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases. The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia.

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.